Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6649)
All Articles published online
|
Publishing Process of This Article
|
Feb 24, 2019 (publication date) through Nov 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Devaux M, Gerard L, Richard C, Bengrine-Lefevre L, Vincent J, Schmitt A, Ghiringhelli F. Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer. World J Clin Oncol 2019; 10(2): 75-85 [PMID: 30815374 DOI: 10.5306/wjco.v10.i2.75] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v10/i2/75.htm |
| Number | Citing Articles |
| 1 |
Kei Muro, Taylor Salinardi, Arvind Rup Singh, Teresa Macarulla. Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data. Cancers 2020; 12(4): 844 doi: 10.3390/cancers12040844
|
| 2 |
Tomas Buchler, Igor Kiss, Jana Hornova, Ondrej Fiala, Marketa Wiesnerova, Michal Svoboda, Jiri Silar, Katerina Kopeckova, Alexandr Poprach, Jindrich Finek, Lubos Petruzelka, Bohuslav Melichar. Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice. Targeted Oncology 2020; 15(2): 193 doi: 10.1007/s11523-020-00705-1
|
| 3 |
Eleonora Lai, Stefano Cascinu, Mario Scartozzi. Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.637823
|
| 4 |
Raquel Claramunt García, Carmen Lucía Muñoz Cid, Andrés Sánchez Ruiz, Juan Francisco Marín Pozo. Bevacizumab and aflibercept in second-line metastatic colorectal cancer: 12 years of experience. European Journal of Clinical Pharmacology 2022; 78(2): 287 doi: 10.1007/s00228-021-03235-5
|
| 5 |
Pu Ge, Abudurosuli Reyila, Xin‐yi Li, Si‐yu Liu, Yi‐xuan Jiang, Ya‐jie Yang, Xia‐lei Li, Ying Bian. Efficacy and safety of aflibercept plus chemotherapy in metastatic colorectal cancer: A systematic review and PRISMA‐Compliant single‐arm Meta‐Analysis of noncomparative clinical studies and randomized controlled trials. Journal of Clinical Pharmacy and Therapeutics 2022; 47(6): 798 doi: 10.1111/jcpt.13610
|